Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Apnimed, Inc.
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
May 23, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
May 09, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
May 07, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
March 06, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
January 22, 2024
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
December 21, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in Upcoming November Investor Conferences
November 06, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
October 31, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
October 18, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in Upcoming October Investor Conferences
October 11, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
October 10, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
October 02, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
September 21, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
September 18, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
September 06, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
APNIMED to Participate in Upcoming Investor Conferences in September
August 30, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
August 28, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
August 01, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
July 12, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Participate in the 2023 BIO International Convention
May 23, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
May 21, 2023
From
Apnimed, Inc.
Via
GlobeNewswire
Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023
May 15, 2023
From
Apnimed, Inc.
Via
Business Wire
Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From
Apnimed, Inc.
Via
Business Wire
Apnimed to Participate in the SVB Securities Global Biopharma Conference
January 25, 2023
From
Apnimed, Inc.
Via
Business Wire
Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)
January 03, 2023
From
Apnimed, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.